GW Pharma's cannabis drug fails in cancer pain study

Otsuka

08/01/2015 12:21

LONDON, Jan 8 (Reuters) - An experimental cannabis drug 
failed to alleviate pain in cancer patients as hoped in a 
clinical study, sending shares in its British maker GW 
Pharmaceuticals  GWP.L  18 percent lower on Thursday. 
    GW, which is developing the drug Sativex for pain in 
collaboration with Japan's Otsuka  4768.T , said the first of 
three late-stage trials found no statistically significant 
difference between subjects using its product and those given a 
placebo. 
 
 (Reporting by Ben Hirschler; Editing by Pravin Char) 
 ((ben.hirschler@thomsonreuters.com; +44 20 7542 5082; Reuters 
Messaging: ben.hirschler.thomsonreuters.com@reuters.net)) 
 
Keywords: GW PHARMA EPILEPSY/